MDRX logo

Veradigm (MDRX)

Profile

Full Name

Veradigm Inc.

Ticker Symbol

MDRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Health Information Services

Country

United States

IPO

July 26, 1999

Indexes

Not included

Website

http://veradigm.com

Employees

2450

Key Details

Price

$4.15(+1.22%)

Market cap

$449.30M(Small cap)

Last Dividend

$5.23

TTM Dividend yield

-

Annual revenue

$588.02M(+1.83% YoY)

Annual EPS

-$0.77(-176.24% YoY)

PE ratio

-

Next earnings date

May 29, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$4.15
MDRX price is $4.15

30-Day Relative Volume

1.98
MDRX 30-day relative volume is 1.98

Price Performance

Price Most recent change

+1.22%
MDRX price was up +1.22% on Apr 15, 2025

Price YTD change

-57.44%
MDRX price is down -57.44% since January 1st

Price 1-year change

-44.3%
MDRX price is down -44.3% year-on-year

Price 3-year change

-81.41%
MDRX price is down -81.41% over the past 3 years

Price Range

Price All-time high

$89.63
MDRX price is currently -95.37% below its historical high of $89.63

Price 3-year low

$3.80
MDRX price is currently +9.21% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$449.30M
MDRX market capitalization is $449.30 million

Market cap 3-year change

-82.46%
MDRX market capitalization is down -82.46% over the past 3 years

Market cap All-time high

$4.32B
MDRX market capitalization is currently -89.60% below its historical high of $4.32 billion

Market cap sector rank

68.01%
MDRX market capitalization is higher than 68.01% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.58%
MDRX shares outstanding is up +0.58% year-on-year

Shares Outstanding 3-Year Change

-5.69%
MDRX shares outstanding is down -5.69% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.38
MDRX beta is 0.38

200-day SMA

$8.37
MDRX price is currently -50.44% below its 200-day simple moving average

50-day SMA

$4.79
MDRX price is currently -13.32% below its 50-day simple moving average

RSI

40.27
MDRX 14-day relative strength index is 40.27

Volume

1.98
MDRX 30-day relative volume is 1.98

ATR

$0.37
MDRX average true range is $0.37

10-day Historical Volatility

52.22%
MDRX 10-day historical volatility is 52.22%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$5.23
MDRX last dividend was $5.23 per share, with an ex-dividend date of October 7, 2008

Next Dividend

-
MDRX next dividend has not yet been announced

Dividend per share

Dividend per share

-
MDRX annual dividend per share value is unknown

Dividend per share Sector Rank

-
MDRX annual dividend per share is unknown

Dividend per share 1-Year Change

-
MDRX annual dividend per share 1-year change is unknown

Dividend per share 3-Year Change

-
MDRX annual dividend per share 3-year change is unknown

Dividend yield

Dividend yield

-
MDRX annual dividend yield value is unknown

Dividend yield Sector Rank

-
MDRX annual dividend yield is unknown

Other

Payout ratio

-
MDRX annual payout ratio value is unknown

Dividends paid

-
MDRX annual dividends paid value is unknown

Free cash flow

$83.30M
MDRX annual free cash flow is $83.30 million

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$588.02M
MDRX annual revenue is $588.02 million

Revenue Analysts estimate

$624.09M
MDRX annual revenue is currently -5.78% lower than the consensus analysts' forecast

Revenue 1-year change

+1.83%
MDRX annual revenue is up +1.83% year-on-year

Revenue Sector rank

75.2%
MDRX annual revenue is higher than 75.2% of companies in Healthcare sector

EPS

EPS

-$0.77
MDRX annual earnings per share is -$0.77

EPS Analysts estimate

$0.33
MDRX annual earnings per share is currently -334.04% lower than the consensus analysts' forecast

EPS 1-year change

-176.24%
MDRX annual earnings per share is down -176.24% year-on-year

EPS Sector rank

61.64%
MDRX annual earnings per share is higher than 61.64% of companies in Healthcare sector

Profit

Gross profit

$308.42M
MDRX annual gross profit is $308.42 million

Gross margin

52.45%
MDRX annual gross profit margin is 52.45%

Operating profit

-$19.55M
MDRX annual operating income is -$19.55 million

Operating margin

-3.33%
MDRX annual operating profit margin is -3.33%

Net income

-$86.46M
MDRX annual net profit is -$86.46 million

Net margin

-14.70%
MDRX annual net profit margin is -14.70%

Expenses

Total expenses

$607.57M
MDRX annual total expenses is $607.57 million

Operating expenses

$327.97M
MDRX annual total operating expenses is $327.97 million

Cost of goods sold

$279.60M
MDRX annual cost of goods sold is $279.60 million

Selling, general & administrative expenses

$169.20M
MDRX annual SGA is $169.20 million

Depreciation and amortization

$115.92M
MDRX annual depreciation & amortization is $115.92 million

Interest expense

$6.35M
MDRX annual interest expense is $6.35 million

Income tax

-$43.81M
MDRX annual income tax is -$43.81 million

EBIT & EBITDA

EBIT

-$57.50M
MDRX annual earnings before interest & taxes is -$57.50 million

EBITDA

$58.42M
MDRX annual EBITDA is $58.42 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.50B
MDRX annual total assets is $1.50 billion

Non current assets

$825.07M
MDRX annual long term assets is $825.07 million

Current assets

$679.65M
MDRX annual total current assets is $679.65 million

Cash and cash equivalents

$446.59M
MDRX annual cash & cash equivalents is $446.59 million

Accounts receivable

$119.15M
MDRX annual accounts receivable is $119.15 million

Inventory

-
MDRX annual inventory value is unknown

Liabilities

Total liabilities

$487.22M
MDRX annual total liabilities is $487.22 million

Long term liabilities

$256.90M
MDRX annual total long term liabilities is $256.90 million

Current liabilities

$230.31M
MDRX annual total current liabilities is $230.31 million

Accounts payable

$30.84M
MDRX annual accounts payable is $30.84 million

Debt

Total debt

$219.44M
MDRX annual total debt is $219.44 million

Total debt 1-year change

-41.16%
MDRX annual total debt is down -41.16% year-on-year

Long term debt

$212.84M
MDRX annual long term debt is $212.84 million

Short term debt

$6.61M
MDRX annual short term debt is $6.61 million

Equity & Capital

Shareholders equity

$1.02B
MDRX annual stockholders equity is $1.02 billion

Book value

$1.02B
MDRX annual book value is $1.02 billion

Retained earnings

$645.81M
MDRX annual retained earnings is $645.81 million

Working capital

$449.33M
MDRX annual working capital is $449.33 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$115.56M
MDRX annual cash flow from operations is $115.56 million

Cash from operations 1-year change

+250.83%
MDRX annual cash flow from operations is up +250.83% year-on-year

Cash from investing

$585.15M
MDRX annual cash flow from investing activities is $585.15 million

Cash from investing 1-year change

+4708.9%
MDRX annual cash flow from investing activities is up +4708.9% year-on-year

Cash from financing

-$444.91M
MDRX annual cash flow from financing activities is -$444.91 million

Cash from financing 1-year change

-71.87%
MDRX annual cash flow from financing activities is down -71.87% year-on-year

CAPEX

CAPEX

$32.27M
MDRX annual capital expenditures is $32.27 million

CAPEX 1-year change

-22.03%
MDRX annual capital expenditures is down -22.03% year-on-year

Free Cash Flow

Free cash flow

$83.30M
MDRX annual free cash flow is $83.30 million

Free cash flow 1-year change

+170.59%
MDRX annual free cash flow is up +170.59% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

52.45%
MDRX annual gross profit margin is 52.45%

Operating margin

-3.33%
MDRX annual operating profit margin is -3.33%

Net margin

-14.70%
MDRX annual net profit margin is -14.70%

ROA & ROE

ROA

-4.53%
MDRX annual return on assets is -4.53%

ROE

-7.27%
MDRX annual return on equity is -7.27%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
MDRX price to earnings ratio value is unknown

PE ratio Sector rank

-
MDRX price to earnings ratio is unknown

PB Ratio

PB ratio

0.44
MDRX price to book ratio is 0.44

PB ratio Sector rank

27.98%
MDRX price to book ratio is higher than 27.98% of companies in Healthcare sector

PS Ratio

PS ratio

0.76
MDRX price to sales ratio is 0.76

PS ratio Sector rank

22.95%
MDRX price to sales ratio is higher than 22.95% of companies in Healthcare sector

Enterprise value

Enterprise value

$222.15M
MDRX enterprise value is $222.15 million

Enterprise value Sector rank

59.97%
MDRX enterprise value is higher than 59.97% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

3.80
MDRX EV/EBITDA is 3.80

EV/EBITDA Sector rank

77.46%
MDRX EV/EBITDA is higher than 77.46% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.95
MDRX annual current ratio is 2.95

Quick ratio

-
MDRX annual quick ratio value is unknown

Leverage

Debt to equity

0.20
MDRX annual debt to equity ratio is 0.20

Interest coverage ratio

-9.05
MDRX annual interest coverage ratio is -9.05

Risk & Stability

Piotroski F-Score

6
MDRX piotroski f-score is 6

Altman Z-Score

1.78
MDRX altman z-score is 1.78

Analyst ratings

Recent major analysts updates

Jan 31, 25 Stephens & Co.
Equal-Weight
May 28, 24 TD Cowen
Buy
Mar 19, 24 Deutsche Bank
Hold
Jan 19, 24 RBC Capital
Outperform
Jan 3, 24 Barclays
Equal-Weight
Nov 14, 23 Stephens & Co.
Equal-Weight
Oct 10, 23 Stephens & Co.
Equal-Weight
Jul 6, 23 Argus Research
Hold
Apr 12, 23 Stephens & Co.
Equal-Weight
Feb 1, 23 Piper Sandler
Neutral

Institutional Ownership

Similar stocks

CAPR logo
Capricor Therapeutics (CAPR)
CGEM logo
Cullinan Oncology (CGEM)
VERV logo
Verve Therapeutics (VERV)
TYRA logo
Tyra Biosciences (TYRA)
CeriBell (CBLL)
Fortrea Holdings (FTRE)
LAB logo
Standard BioTools (LAB)
SAGE logo
Sage Therapeutics (SAGE)
SVA logo
Sinovac Biotech (SVA)
  • What is the ticker symbol for Veradigm?
  • Does Veradigm pay dividends?
  • What sector is Veradigm in?
  • What industry is Veradigm in?
  • What country is Veradigm based in?
  • When did Veradigm go public?
  • Is Veradigm in the S&P 500?
  • Is Veradigm in the NASDAQ 100?
  • Is Veradigm in the Dow Jones?
  • When was Veradigm's last earnings report?
  • When does Veradigm report earnings?
  • Should I buy Veradigm stock now?

What is the ticker symbol for Veradigm?

The ticker symbol for Veradigm is NASDAQ:MDRX

Does Veradigm pay dividends?

No, Veradigm does not pay dividends

What sector is Veradigm in?

Veradigm is in the Healthcare sector

What industry is Veradigm in?

Veradigm is in the Health Information Services industry

What country is Veradigm based in?

Veradigm is headquartered in United States

When did Veradigm go public?

Veradigm's initial public offering (IPO) was on July 26, 1999

Is Veradigm in the S&P 500?

No, Veradigm is not included in the S&P 500 index

Is Veradigm in the NASDAQ 100?

No, Veradigm is not included in the NASDAQ 100 index

Is Veradigm in the Dow Jones?

No, Veradigm is not included in the Dow Jones index

When was Veradigm's last earnings report?

Veradigm's most recent earnings report was on Mar 19, 2025

When does Veradigm report earnings?

The next expected earnings date for Veradigm is May 29, 2025

Should I buy Veradigm stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page